{"groups":[{"description":"300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.","id":"FG000","title":"DKN-01 Monotherapy in Recurrent EEC"},{"description":"300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 administered by IV infusion.","id":"FG001","title":"DKN-01+Paclitaxel in Recurrent EEC"},{"description":"300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.","id":"FG002","title":"DKN-01 Monotherapy in Recurrent EOC"},{"description":"300mg DKN-01+paclitaxel in recurrent EOC. DKN-01and paclitaxel administered by IV infusion.","id":"FG003","title":"DKN-01+Paclitaxel in Recurrent EOC"},{"description":"300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"FG004","title":"DKN-01 300mg Monotherapy in Carcinosarcoma"},{"description":"600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"FG005","title":"DKN-01 600mg Monotherapy in Carcinosarcoma"},{"description":"300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"FG006","title":"DKN-01 300mg + Paclitaxel in Carcinosarcoma"},{"description":"600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"FG007","title":"DKN-01 600 mg + Paclitaxel in Carcinosarcoma"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"19"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"12"}],"comment":"Number Started is the Safety Analysis Set defined as all subjects who received \\>= 1 administration of assigned study treatment (DKN-01 or paclitaxel).Subjects with carcinosarcoma were initially enrolled in the EEC group to receive monotherapy or DKN-01+paclitaxel, but as part of a subsequent protocol amendment, carcinosarcoma subjects were enrolled \\& received 600mg DKN-01 or 600mg DKN-01+paclitaxel. Results are reported by disease type and treatment received.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"19"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"10"}],"comment":"Number Completed is the Evaluable Analysis Set defined as all subjects who received any amount of DKN-01 and had at least 1 evaluated post-baseline RECIST assessment or were discontinued due to death.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}